Loading...
XNYS
BSX
Market cap147bUSD
Apr 02, Last price  
100.05USD
1D
-1.18%
1Q
11.94%
Jan 2017
362.55%
Name

Boston Scientific Corp

Chart & Performance

D1W1MN
P/E
79.86
P/S
8.84
EPS
1.25
Div Yield, %
—
Shrs. gr., 5y
1.05%
Rev. gr., 5y
9.30%
Revenues
16.75b
+17.61%
6,283,000,0007,821,000,0008,357,000,0008,050,000,0008,188,000,0007,806,000,0007,622,000,0007,249,000,0007,143,000,0007,380,000,0007,477,000,0008,386,000,0009,048,000,0009,823,000,00010,735,000,0009,913,000,00011,888,000,00012,682,000,00014,240,000,00016,747,000,000
Net income
1.85b
+16.32%
628,000,000-3,577,000,000-495,000,000-2,072,000,000-1,025,000,000-1,065,000,000441,000,000-4,068,000,000-121,000,000267,000,000-239,000,000347,000,000104,000,0001,671,000,0004,700,000,000-140,000,0001,041,000,000698,000,0001,593,000,0001,853,000,000
CFO
3.44b
+37.24%
903,000,0001,845,000,000934,000,0001,216,000,000835,000,000325,000,0001,008,000,0001,260,000,0001,082,000,0001,269,000,000600,000,000972,000,0001,426,000,000310,000,0001,836,000,0001,508,000,0001,870,000,0001,526,000,0002,503,000,0003,435,000,000
Earnings
Apr 22, 2025

Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
URL
https://www.bostonscientific.com/en-US/Home.html
IPO date
May 19, 1992
Employees
45,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
16,747,000
17.61%
14,240,000
12.29%
12,682,000
6.68%
Cost of revenue
6,872,000
5,759,000
5,326,000
Unusual Expense (Income)
NOPBT
9,875,000
8,481,000
7,356,000
NOPBT Margin
58.97%
59.56%
58.00%
Operating Taxes
436,000
393,000
443,000
Tax Rate
4.42%
4.63%
6.02%
NOPAT
9,439,000
8,088,000
6,913,000
Net income
1,853,000
16.32%
1,593,000
128.22%
698,000
-32.95%
Dividends
(28,000)
(55,000)
Dividend yield
0.03%
0.08%
Proceeds from repurchase of equity
364,000
272,000
BB yield
-0.43%
-0.41%
Debt
Debt current
1,778,000
531,000
20,000
Long-term debt
9,495,000
9,356,000
9,614,000
Deferred revenue
311,000
289,000
Other long-term liabilities
1,870,000
1,267,000
1,398,000
Net debt
10,859,000
8,609,000
8,299,000
Cash flow
Cash from operating activities
3,435,000
2,503,000
1,526,000
CAPEX
(790,000)
(711,000)
(612,000)
Cash from investing activities
(5,687,000)
(2,574,000)
(2,011,000)
Cash from financing activities
1,814,000
5,000
(548,000)
FCF
8,718,000
6,558,000
6,364,000
Balance
Cash
414,000
865,000
928,000
Long term investments
413,000
407,000
Excess cash
566,000
700,900
Stockholders' equity
3,198,000
1,133,000
(464,000)
Invested Capital
34,619,000
29,785,000
28,775,000
ROIC
29.31%
27.62%
24.01%
ROCE
28.40%
27.59%
25.85%
EV
Common stock shares outstanding
1,485,900
1,463,500
1,439,700
Price
89.32
54.51%
57.81
24.94%
46.27
8.92%
Market cap
132,720,588
56.87%
84,604,935
27.01%
66,614,919
9.37%
EV
143,812,588
93,461,935
74,913,919
EBITDA
11,144,000
9,677,000
8,492,000
EV/EBITDA
12.90
9.66
8.82
Interest
305,000
265,000
470,000
Interest/NOPBT
3.09%
3.12%
6.39%